The Behnke Group, led by Bill Behnke, is proud to support the efforts of Cizzle Bio, Inc. in revolutionizing lung cancer detection through an exclusive licensing and partnership agreement for the CIZ1B biomarker test in North America. This groundbreaking deal is a significant step towards improving early lung cancer detection in the USA and Canada, a vital need in today’s healthcare landscape.
As part of this strategic partnership, Cizzle Bio, Inc. has secured a $300,000 initial royalty payment and an ongoing 10% royalty on gross sales after tax with guaranteed minimum payments totaling $2 million over the next 30 months.
Key Highlights of the Agreement:
Exclusive North American Rights:
Cizzle Bio, Inc. has exclusive rights to the CIZ1B biomarker technology for early lung cancer detection, positioning the company to serve one of the largest global healthcare markets.
Initial Payment & Revenue Streams:
The agreement includes an upfront payment of $300,000 and guaranteed royalty payments over the next 30 months, providing Cizzle Bio, Inc. with steady revenue streams to pursue its strategic milestones.
Equity Stake in BIO:
Cizzle Biotechnology Holdings will share in the success of BIO by receiving an equity stake, aligning both parties’ long-term goals for success.
Partnership with Moffitt Cancer Center:
BIO has already partnered with leading institutions like Moffitt Cancer Center, one of the top cancer facilities in the US, to further evaluate the efficacy of the CIZ1B biomarker in clinical settings.
Future Milestones:
BIO aims to launch the CIZ1B test by April 2025, following CLIA accreditation and securing approved reimbursement codes, making this innovative diagnostic tool accessible to patients across the USA and Canada.
Bill Behnke, CEO of The Behnke Group and Cizzle Bio, Inc., shared his enthusiasm about the partnership:
“Another very important milestone achieved in our tireless efforts to screen patients early and save lives. Cizzle Bio Inc is excited about commercializing all the wonderful research work that our UK partners have progressed over the years in lung cancer. Cizzle Bio, through our vast network in the USA is in discussions with multiple hospitals, cancer centers, advocacy associations, pulmonary critical care and primary care physician groups and screening programs. Our mission is clear, to screen as many patients as we can out of the 14.2 million recommended by the US Preventative Services Task Force that should be tested for lung cancer each year, resulting in saving millions of lives and increasing the 5.5% of people currently being test to a much more robust number.”
This agreement aligns with The Behnke Group’s mission to support life-changing innovations in healthcare, providing companies like Cizzle Bio, Inc. with the expertise and resources they need to succeed.
For more details on how The Behnke Group is facilitating advancements in healthcare, visit our website or get in touch with us today.